Skip to main content

Table 1 Demographic characteristics of participators at baseline

From: Cobalt exposure and pulmonary function reduction in chronic obstructive pulmonary disease patients: the mediating role of club cell secretory protein

Characteristic

All participators

Tertile of blood Co (ppm)

P

Tertile 1 (<0.635)

Tertile 2 (0.635 ~ 1.230)

Tertile 3 (>1.230)

N

771

257

257

257

 

Age, years

74.0 ± 0.32

74.15 ± 0.54

74.19 ± 0.56

73.67 ± 0.54

0.756

Male, n (%)

567 (73.54)

193 (75.10)

193 (73.10)

181 (70.43)

0.383

BMI (kg/m2)

22.19 ± 0.33

23.06 ± 0.33

22.68 ± 0.46

22.13 ± 0.16

0.095

Enrolled season, n (%)

    

0.002

Spring

176 (22.83)

58 (22.57)

70 (27.24)

48 (18.68)

 

Summer

119 (15.43)

45 (17.51)

39 (15.18)

35 (13.62)

 

Autumn

228 (29.57)

63 (24.51)

63 (24.51)

102 (39.69)

 

Winter

247 (32.04)

90 (35.02)

85 (33.07)

72 (28.02)

 

Smoking status, n (%)

    

0.019

None

330 (42.80)

118 (52.85)

109 (41.06)

103 (39.93)

 

Former

230 (29.83)

87 (28.14)

75 (24.34)

68 (34.60)

 

Current

211 (26.37)

52 (19.01)

73 (34.60)

86 (25.47)

 

Smoking amount, pack-year

41.38 ± 0.58

35.26 ± 0.91

43.07 ± 0.85

46.36 ± 1.11

0.001

Self-cooking, n (%)

594 (78.04)

180 (70.04)

203 (78.99)

211 (82.10)

0.003

Drinkers, n (%)

245 (31.78)

81 (31.52)

80 (31.13)

84 (32.68)

0.925

Comorbidities, n (%)

     

Hypertension

280 (36.32)

88 (34.34)

94 (36.58)

98 (38.13)

0.653

Diabetes mellitus

78 (9.86)

26 (10.12)

16 (6.23)

36 (14.01)

0.014

Coronary disease

119 (15.43)

35 (13.62)

45 (17.51)

49 (19.07)

0.227

Cerebrovascular diseases

90 (11.67)

24 (9.34)

26 (10.12)

40 (15.560)

0.065

Inhaled drug for COPD, n (%)

     

SABA

426 (55.25)

116 (45.14)

117 (45.53)

193 (75.10)

<0.001

SAMA

75 (9.73)

21 (8.17)

22 (8.26)

32 (12.45)

0.228

LABA

321 (41.63)

104 (40.47)

104 (40.47)

113 (43.97)

0.649

LAMA

132 (17.12)

47 (18.29)

47 (18.29)

38 (14.79)

0.493

ICS

626 (81.19)

202 (78.60)

207 (80.54)

217 (84.44)

0.226

CC16 (pg/mL)

0.55 (0.29, 1.04)

0.98 (0.62, 1.35)

0.50 (0.26, 0.89)

0.34 (0.18, 0.54)

<0.001

Pulmonary function

     

FVC (L)

2.29 ± 0.05

2.71 ± 0.07

2.36 ± 0.07

1.82 ± 0.07

<0.001

FEV1 (L)

1.80 ± 0.04

2.23 ± 0.08

1.73 ± 0.08

1.47 ± 0.06

<0.001

FEV1/FVC (%)

59.55 ± 0.82

65.67 ± 1.59

59.78 ± 1.43

54.37 ± 1.07

<0.001

FEV1 (%)

61.99 ± 1.74

79.29 ± 2.63

62.71 ± 2.40

43.50 ± 2.77

<0.001

  1. Bold values indicate statistical significance
  2. BMI: body mass index; SABA: short-acting beta agonist; SAMA: short-acting muscarinic antagonist; LABA: long-acting beta agonist; LAMA: long-acting muscarinic antagonist; ICS: inhaled corticosteroids; FVC: forced vital capacity; FEV1: forced expiratory volume in the first second